Back to top
more

MannKind (MNKD)

(Real Time Quote from BATS)

$4.03 USD

4.03
1,410,691

+0.11 (2.81%)

Updated Aug 5, 2025 03:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options

by Zacks Equity Research

MannKind Corp. (MNKD) warrants investors' attention based on moves in the options market lately.

    Zacks Equity Research

    Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA

    by Zacks Equity Research

    Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.

      Zacks Equity Research

      BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

      by Zacks Equity Research

      The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).

        Zacks Equity Research

        Galena Biopharma Reveals Regulatory Pathway for GALE-401

        by Zacks Equity Research

        Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.

          Zacks Equity Research

          Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger

          by Zacks Equity Research

          Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger

            Zacks Equity Research

            MannKind (MNKD) Shares March Higher, Can It Continue?

            by Zacks Equity Research

            As of late, it has definitely been a great time to be an investor in MannKind Corporation (MNKD).

              Zacks Equity Research

              Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data

              by Zacks Equity Research

              Anthera (ANTH) reported unimpressive top-line data from a phase III study on Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency.

                Zacks Equity Research

                Profit from These 5 Stocks with Rising P/E Ratio

                by Zacks Equity Research

                Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

                  Zacks Equity Research

                  Alexion Soliris Fails in Phase II/III Delayed Graft Function Study

                  by Zacks Equity Research

                  Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.

                    Zacks Equity Research

                    Celgene (CELG) Otezla Approved in Japan for Two Indications

                    by Zacks Equity Research

                    Celgene's (CELG) Otezla approved for the treatment of plaque psoriasis and psoriatic arthritis in Japan.

                      Sanghamitra Saha headshot

                      3 Low P/E Momentum ETFs & Stocks for Uncertain Santa Rally

                      by Sanghamitra Saha

                      Can Santa cause a rally this year? If you have some hope, try these three 3 low P/E momentum ETFs and stocks.

                        Zacks Equity Research

                        Clovis Scales 52-Week High on Early FDA Nod for Rubraca

                        by Zacks Equity Research

                        Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.

                          Ryan McQueeney headshot

                          Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars

                          by Ryan McQueeney

                          While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany, the U.S. indexes were all green on Monday.

                            Zacks Equity Research

                            Trovagene to Focus More on Liquid Biopsy Testing Market

                            by Zacks Equity Research

                            Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.

                              Zacks Equity Research

                              athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017

                              by Zacks Equity Research

                              athenahealth Inc. (ATHN) reaffirmed its full-year 2016 guidance and issued a stable guidance for 2017.

                                Zacks Equity Research

                                Intuitive Surgical (ISRG) Raises Share Buyback to $3 Billion

                                by Zacks Equity Research

                                Intuitive Surgical Inc. (ISRG) increased the authorized amount available under the company's share repurchase program to $3.0 billion.

                                  Zacks Equity Research

                                  Envision Healthcare Acquires Desert Mountain Consultants

                                  by Zacks Equity Research

                                  Envision Healthcare Corporation (EVHC), a provider of physician-led outsourced medical services to consumers, hospitals and healthcare systems in the U.S., recently announced the acquisition of Desert Mountain Consultants in Anesthesia, Inc.

                                    Zacks Equity Research

                                    Proteon Slips to 52-Week Low on Kidney Disease Study Data

                                    by Zacks Equity Research

                                    Proteon's (PRTO) shares hit a 52-week low after reporting poor top-line phase III data on vonapanitase in patients with chronic kidney disease.

                                      Zacks Equity Research

                                      Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger

                                      by Zacks Equity Research

                                      Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger

                                        Zacks Equity Research

                                        Buy 5 Stocks with Rising P/E to Bust a Common Myth

                                        by Zacks Equity Research

                                        Forget undervalued stocks, buy these top-ranked stocks with rising P/E.

                                          Zacks Equity Research

                                          Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails

                                          by Zacks Equity Research

                                          Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.

                                            Zacks Equity Research

                                            Theravance Stock Up on Fast Track Status for Velusetrag

                                            by Zacks Equity Research

                                            Theravance (TBPH) received Fast Track status from the FDA for velusetrag for idiopathic and diabetic gastroparesis.